MARKET

GNPX

GNPX

Genprex Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.499
+0.009
+0.60%
Opening 10:56 08/11 EDT
OPEN
1.520
PREV CLOSE
1.490
HIGH
1.540
LOW
1.499
VOLUME
19.98K
TURNOVER
21.16K
52 WEEK HIGH
3.620
52 WEEK LOW
1.170
MARKET CAP
71.79M
P/E (TTM)
-3.7976
1D
5D
1M
3M
1Y
5Y
Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that Company manufacturing leadership will present session...
PR Newswire · 07/13 11:00
Genprex to Present at Upcoming June Investor Conferences
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming inve...
PR Newswire · 06/02 11:00
Genprex to Present at Upcoming Investor Conference in May 2022
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Var...
PR Newswire · 05/19 12:15
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 05/17 12:23
Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Medical Officer, Mark Berger, M.D., will be...
PR Newswire · 05/09 12:15
Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a shareholder letter and corporate upda...
PR Newswire · 05/05 12:30
Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its executive leaders will be providing an overview o...
PR Newswire · 04/18 12:15
Genprex's begins patient enrollment in Phase 1/2 trial testing lung cancer therapy
Genprex (NASDAQ:GNPX) said it was opening patient enrollment for Phase 1/2 trial testing its lead drug candidate, Reqorsa in combination with Merck's Keytruda in patients with late-stage non-small cell lung cancer (NSCLC). The
Seekingalpha · 03/31 13:40
More
No Data
Learn about the latest financial forecast of GNPX. Analyze the recent business situations of Genprex Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GNPX stock price target is 6.50 with a high estimate of 8.00 and a low estimate of 5.00.
High8.00
Average6.50
Low5.00
Current 1.499
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 60
Institutional Holdings: 4.77M
% Owned: 9.95%
Shares Outstanding: 47.90M
TypeInstitutionsShares
Increased
8
216.23K
New
9
116.72K
Decreased
11
1.39M
Sold Out
9
1.71M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.28%
Pharmaceuticals & Medical Research
-0.16%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Secretary
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Executive Vice President/General Counsel
Catherine Vaczy
Chief Technology Officer
Hemant Kumar
Other
Mark Berger
Independent Director
Brent Longnecker
Independent Director
Jose Moreno Toscano
Independent Director
William Wilson
No Data
No Data
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogen therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a multifunctional gene that helps in cancer suppression and normal cell regulation. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Webull offers kinds of Genprex Inc stock information, including NASDAQ:GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.